PATHOMIQ today announced that Myriad Genetics has launched Prolaris® + AI, a next-generation prostate cancer test that integrates PATHOMIQ’s artificial intelligence-powered digital pathology technology with the established Prolaris molecular assay. The commercial launch marks an important milestone in bringing AI-enabled pathology into routine clinical decision-making for patients with localized prostate cancer. The new Prolaris + AI Test combines three complementary sources of information in a single clinical report:
- Clinical and pathological risk factors
- The Prolaris® Cell Cycle Risk (CCR) molecular score
- A PATHOMIQ AI-derived digital pathology biomarker generated from routine H&E biopsy images
Together, these complementary insights are designed to help physicians determine whether patients with low- or favorable intermediate-risk prostate cancer are appropriate candidates for active surveillance while providing additional information to personalize surveillance intensity over time.
Bringing AI into Clinical PracticeActive surveillance has become the preferred management strategy for many men diagnosed with low-risk prostate cancer. However, accurately identifying patients who are most likely to remain suitable for surveillance remains a significant clinical challenge.By analyzing routinely acquired digital pathology images, PATHOMIQ’s AI technology extracts quantitative morphological features that are not readily discernible through conventional microscopic assessment. Integrated with molecular and clinical information, these image-derived biomarkers provide an additional layer of information to support individualized patient management.According to Myriad, the AI-enhanced test estimates the likelihood of Gleason score upgrading at a future biopsy, helping clinicians tailor surveillance strategies with greater confidence.
Built on Clinical ValidationThe AI component incorporated into Prolaris + AI was developed and validated using large cohorts of patients eligible for active surveillance. In data reported by Myriad, the model was trained using biopsy images from 998 patients and independently validated in an additional cohort of 296 patients, demonstrating that the AI-derived metric provides independent prognostic information beyond traditional clinical variables.The integrated report combines long-term prognostic assessment from the Prolaris molecular score with short-term risk estimation generated from PATHOMIQ AI, enabling clinicians to evaluate complementary aspects of disease biology without requiring additional tissue samples.
Expanding the Impact of Digital Pathology AIThe launch represents another significant milestone in PATHOMIQ’s mission to transform cancer diagnosis and treatment through clinically validated artificial intelligence.PATHOMIQ’s platform analyzes routine digital pathology images to uncover predictive and prognostic information that can support treatment selection and patient management while fitting seamlessly into existing pathology workflows.Earlier in 2025, PATHOMIQ and Myriad Genetics announced a strategic collaboration to integrate PATHOMIQ’s AI technology into Myriad’s oncology portfolio. The commercial launch of Prolaris + AI represents the first clinical product resulting from that collaboration.
Commercial AvailabilityAccording to Myriad Genetics, the AI metric is available for Prolaris Biopsy Tests performed on U.S. patient samples processed beginning May 29, 2026, excluding New York State at launch, with additional availability expected following state-specific approvals.
About PATHOMIQPATHOMIQ develops artificial intelligence solutions that unlock clinically actionable information from routine digital pathology images. By combining advanced machine learning with rigorous clinical validation, PATHOMIQ enables precision diagnostics that support prognosis, treatment selection, and personalized patient care across multiple cancer types.
To learn more about PATHOMIQ INC., please visit www.pathomiq.com.
View original content here.
